Market Overview

Valeant Pharmaceuticals Acquires Visudyne From QLT for $62.5M

Share:
Related VRX
Morgan Stanley Reiterates Overweight, Raises Price Target On Valeant Pharmaceuticals On New Proforma Model For SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Stocks Break Out Again But May Be Running On Fumes (Seeking Alpha)

Valeant Pharmaceuticals International (NYSE: VRX) announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc. (NASDAQ: QLTI). Valeant paid $62.5 million upfront for all U.S. rights and available inventories for Visudyne, which had U.S. revenue of approximately $21 million in 2011, and another $50 million upfront for rights to non-US royalties on Visudyne sales, which were approximately $14 million in 2011. Valeant has also agreed to pay an additional $5 million in contingent payments relating to the development of QLT's laser program in the United States and up to $15 million in contingent payments relating to the non-U.S. royalties. Additionally, Valeant has manufacturing rights and assumed a supply agreement for outside of United States. The transaction is expected to be immediately accretive.

"We are excited about the opportunity to add a complementary product to our growing ophthalmology business," stated J. Michael Pearson, chairman and chief executive officer.  "Not only will we be able to use Visudyne to better leverage our current ophthalmology sales force with a complementary product to Macugen, we are

See full press release

Posted-In: News Guidance Management M&A Global

 

Related Articles (QLTI + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→